吉满生物-DDXCELL 用心做好细胞，为更好的靶向药

LMD-009

C-C Chemokine Receptor Type 8 (CCR8) Ligands

Pharmacological Tools

Biological Testing

NOT DETERMINED

Takeda Oncology (Originator)

LMD-A

C-C Chemokine Receptor Type 8 (CCR8) Ligands

Antiallergy/Antiasthmatic Drugs

Biological Testing

Asthma

Takeda Oncology (Originator)

BMS-986340

Anti-CCR8 (C-C Chemokine Receptor Type 8)

Oncolytic Drugs

Preclinical

Cancer

Bristol-Myers Squibb (Originator)

JTX-1811

Anti-CCR8 (C-C Chemokine Receptor Type 8)

Oncolytic Drugs

Preclinical

Cancer

Gilead Jounce Therapeutics (Originator)

SRF-114

Anti-CCR8 (C-C Chemokine Receptor Type 8)

Oncolytic Drugs

Preclinical

Cancer

Surface Oncology Vaccinex (Originator)

HBM-1022

Anti-CCR8 (C-C Chemokine Receptor Type 8)

Oncolytic Drugs

Preclinical

Cancer

Harbour BioMed (Originator)

FPA-157

Anti-CCR8 (C-C Chemokine Receptor Type 8)

Solid Tumors Therapy

Preclinical

Cancer, solid tumor

Amgen (Originator)

NI-1801

双抗，CD47 antagonist（CD47）;Mesothelin modulator（MSLN

癌症;实体瘤

Preclinical

肿瘤

Light Chain Bioscience

IBI-322

双抗，CD47 antagonist（CD47）;Programmed cell death lig

晚期实体瘤;食道肿瘤;头颈部肿瘤;血液肿瘤;肝肿瘤;肺部肿瘤;子宫颈癌

Phase I

肿瘤

信达生物

TJ-011133;TJC-4；lemzoparlimab

单抗，CD47 antagonist（CD47）

急性骨髓性白血病;晚期实体瘤;淋巴瘤;骨髓增生异常综合征;非霍奇金淋巴瘤

Phase I/II

肿瘤

天境生物

DSP-107

双抗，CD47 antagonist（CD47）;CDw137 agonist（CDw137）

晚期实体瘤;弥漫性大B细胞淋巴瘤;转移性非小细胞肺癌;鳞状细胞癌

Phase I/II

肿瘤

KAHR Medical Ltd

Magrolimab (Generic) 5F9 (Code) 90YIEHRFJ9 (Code) GS-4721 (Code) Hu5F9-G4 (Code) ONO-7913 (Code)

Anti-CD47 (Leukocyte Surface Antigen CD47)

Bladder Cancer Therapy

Breast Cancer Therapy

Colorectal Cancer Therapy

Hematological Cancer Therapy

Hematopoiesis Disorders Therapy

Lymphoma Therapy

Multiple Myeloma Therapy

Myelodysplastic Syndrome Therapy

Myeloid Leukemia Therapy

Non-Hodgkin's Lymphoma Therapy

Ovarian Cancer Therapy

Solid Tumors Therapy

Phase III

Acute myeloid leukemia

Cancer

Cancer, bladder (urothelial carcinoma)

Cancer, breast metastatic

Cancer, colorectal

Cancer, ovary

Cancer, solid tumor

Fanconi anemia

Hematologic-blood cancer

Hodgkin lymphoma (classical)

Lymphoma, diffuse large B-cell

Lymphoma, follicular

Lymphoma, marginal zone

Multiple myeloma

Myelodysplasia

Non-Hodgkin lymphoma

Triple negative breast cancer

Forty Seven (Gilead)

Gilead

Ono

Stanford University (Originator)

University of Oxford

ABDNAZ (Code) RRx-001 (Code)

Nitric Oxide (NO) Donors

Leukocyte Surface Antigen CD47/SIRPA Interaction Inhibitors

Cancer of Unspecified Body Location/System

Colorectal Cancer Therapy

Digestive/Gastrointestinal Cancer Therapy

Glioblastoma Multiforme Therapy

Lymphoma Therapy

Neurologic Cancer Therapy

Non-Small Cell Lung Cancer Therapy

Ovarian Cancer Therapy

Small Cell Lung Cancer Therapy

Solid Tumors Therapy

Treatment of Poisoning

Phase III

Acute radiation syndrome

Cancer, colorectal (adenocarcinoma)

Cancer, colorectal metastatic

Cancer, lung (non-small cell) (NSCLC)

Cancer, lung (small cell) (SCLC)

Cancer, metastatic (to brain)

Cancer, ovary (epithelial)

Cancer, solid tumor

Cholangiocarcinoma

Glioblastoma multiforme

Glioma

Lymphoma

Neuroendocrine cancer

Alliant Techsystems (ATK) (Originator)

EpicentRx (Originator)

RadioRx (EpicentRx)

ALX-148 (Code)

Leukocyte Surface Antigen CD47/SIRPA Interaction Inhibitors

Gastric Cancer Therapy

Head and Neck Cancer Therapy

Myelodysplastic Syndrome Therapy

Non-Hodgkin's Lymphoma Therapy

Solid Tumors Therapy

Phase II

Cancer, gastroesophageal junction

Cancer, gastrointestinal

Cancer, head and neck (squamous cell carcinoma)

Cancer, solid tumor

Cancer, stomach

Myelodysplasia

Non-Hodgkin lymphoma

ALX Oncology (Originator)

Alexo Therapeutics (ALX Oncology)

AK-117 (Code)

Anti-CD47 (Leukocyte Surface Antigen CD47)

Myelodysplastic Syndrome Therapy

Non-Hodgkin's Lymphoma Therapy

Solid Tumors Therapy

Phase I/II

Cancer, solid tumor

Myelodysplasia

Non-Hodgkin lymphoma

Akeso Biopharma (Originator)

Lemzoparlimab (Generic) ABBV-IMAB-TJC4 (Code) TJ-011133 (Code) TJC-4 (Code)

Anti-CD47 (Leukocyte Surface Antigen CD47)

Lymphoma Therapy

Myelodysplastic Syndrome Therapy

Myeloid Leukemia Therapy

Solid Tumors Therapy

Phase I/II

Acute myeloid leukemia

Cancer

Cancer, solid tumor

Lymphoma

Myelodysplasia

AbbVie

I-Mab Biopharma (Originator)

DSP-107 (Code) SIRPa-41BBL (Code)

Tumor Necrosis Factor Receptor Superfamily Member 9 (TNFRSF9, CD137, 4-1BB) Ligands

Drugs Targeting Leukocyte Surface Antigen CD47

Hematological Cancer Therapy

Non-Small Cell Lung Cancer Therapy

Solid Tumors Therapy

Phase I/II

Cancer, lung (non-small cell) (NSCLC)

Cancer, solid tumor

Hematologic-blood cancer

KAHR Medical (Originator)

Letaplimab (Generic) IBI-188 (Code)

Anti-CD47 (Leukocyte Surface Antigen CD47)

Myelodysplastic Syndrome Therapy

Myeloid Leukemia Therapy

Non-Hodgkin's Lymphoma Therapy

Ovarian Cancer Therapy

Solid Tumors Therapy

Phase I/II

Acute myeloid leukemia

Cancer

Cancer, ovary

Cancer, solid tumor

Myelodysplasia

Non-Hodgkin lymphoma

Innovent Biologics (Originator)

AO-176 (Code)

Anti-CD47 (Leukocyte Surface Antigen CD47)

Lymphoma Therapy

Multiple Myeloma Therapy

Solid Tumors Therapy

Phase I/II

Cancer, solid tumor

Lymphoma

Multiple myeloma

Arch Oncology (Originator)

SIRPa-IgG4 Fc (Code) TTI-622 (Code)

Leukocyte Surface Antigen CD47/SIRPA Interaction Inhibitors

Lymphoma Therapy

Multiple Myeloma Therapy

Myeloid Leukemia Therapy

Non-Hodgkin's Lymphoma Therapy

Ovarian Cancer Therapy

Phase I/II

Acute myeloid leukemia

Cancer, ovary

Lymphoma

Lymphoma, diffuse large B-cell

Multiple myeloma

Trillium Therapeutics

University Health Network (UHN) (Originator)

IBI-322 (Code)

Anti-CD47 (Leukocyte Surface Antigen CD47)

Anti-PD-L1 (CD274)

Hematological Cancer Therapy

Solid Tumors Therapy

Phase I

Cancer, solid tumor

Hematologic-blood cancer

Innovent Biologics (Originator)

ZL-1201 (Code)

Anti-CD47 (Leukocyte Surface Antigen CD47)

Lymphoma Therapy

Oncolytic Drugs

Solid Tumors Therapy

Phase I

Cancer

Cancer, solid tumor

Lymphoma

ZAI Lab (Originator)

SIRPa-Fc-CD40L ARC (Code) SIRPalpha- Fc-CD40L (Code) SIRPalpha-Fc-CD40L (Code) SL-172154 (Code)

Drugs Targeting CD40 Ligand (CD40LG; CD154)

Drugs Targeting Leukocyte Surface Antigen CD47

Female Reproductive System Cancer Therapy

Head and Neck Cancer Therapy

Ovarian Cancer Therapy

Skin Cancer Therapy

Phase I

Cancer, fallopian tube

Cancer, head and neck (squamous cell carcinoma)

Cancer, ovary

Cancer, skin

Carcinoma, primary peritoneal (ovarian)

Shattuck Labs (Originator)

IMC-002 (Code)

Anti-CD47 (Leukocyte Surface Antigen CD47)

Lymphoma Therapy

Solid Tumors Therapy

Phase I

Cancer

Cancer, solid tumor

Lymphoma

3D Medicines

ImmuneOncia Therapeutics

Sorrento Therapeutics (Originator)

SRF-231 (Code)

Anti-CD47 (Leukocyte Surface Antigen CD47)

Hematological Cancer Therapy

Lymphocytic Leukemia Therapy

Lymphoma Therapy

Multiple Myeloma Therapy

Solid Tumors Therapy

Phase I

Cancer

Cancer, solid tumor

Chronic lymphocytic leukemia

Hematologic-blood cancer

Lymphoma, Burkitt

Multiple myeloma

Surface Oncology (Originator)

BI-765063 (Code) Effi-DEM (Code) OSE-172 (Code)

Leukocyte Surface Antigen CD47/SIRPA Interaction Inhibitors

Anti-SIRPA (Tyrosine-Protein Phosphatase Non-Receptor Type Substrate 1; SHPS-1)

Solid Tumors Therapy

Phase I

Cancer, solid tumor

Boehringer Ingelheim

OSE Immunotherapeutics (Originator)

－

Anti-CD47 (Leukocyte Surface Antigen CD47)

Breast Cancer Therapy

Phase I

Cancer, breast

Cancer Treatment Centers of America (Originator)